Document Detail

Double bifurcation lesion treated with double Tryton sidebranch stent, first case report.
MedLine Citation:
PMID:  23378273     Owner:  NLM     Status:  Publisher    
The optimal percutaneous treatment strategy for coronary bifurcation lesions is still unknown. Several dedicated coronary bifurcation stents, such as the Tryton Side Branch Stent (TM) (Tryton Medical, Durham, NC, USA) have been developed to improve clinical outcomes. We present a double bifurcation lesion case treated with two Tryton sidebranch stents, with a single drug eluting stent covering the main vessel and both bifurcations. © 2013 Wiley Periodicals, Inc.
Leire Unzué; Eulogio García; Carlos Almería
Related Documents :
23378273 - Double bifurcation lesion treated with double tryton sidebranch stent, first case report.
16013653 - Lipohyperplasia of the ileocecal valve as a cause of intussusception.
10611843 - Serological evidence of chlamydia pneumoniae lipopolysaccharide antibodies in atheroscl...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-4
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  -     ISSN:  1522-726X     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Wiley Periodicals, Inc.
Hospital Universitario Madrid Montepríncipe Avda. Montepríncipe 25, Boadilla del Monte, Madrid. Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effortful retrieval reduces hippocampal activity and impairs incidental encoding.
Next Document:  Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer.